✦ LIBER ✦

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

✍ Scribed by Alan K. Burnett; Donald Milligan; Anthony Goldstone; Archibald Prentice; Mary-Frances McMullin; Michael Dennis; Elizabeth Sellwood; Monica Pallis; Nigel Russell; Robert K. Hills; Keith Wheatley; on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Study Group

Book ID: 108676210
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 420 KB
Volume: 145
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07604.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Randomized trial of two schedules of low

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

✍ Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB